Meth-1

Meth-1 is a protein that in humans is encoded by the ADAMTS8 gene. ADAMTS8 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The enzyme encoded by this gene excises angiogenesis inhibitor METH-1 in vivo and may play a role in cancer development.

Function

Meth-1 is a secreted enzyme that has been shown to inhibit angiogenesis, the process through which new blood vessels form from pre-existing vessels. This is achieved by the cleavage of extracellular matrix components, which disrupts the structural integrity of the blood vessels and prevents their growth. This function has led to interest in Meth-1 as a potential therapeutic target in diseases characterized by excessive angiogenesis, such as cancer and macular degeneration.

Clinical significance

Given its role in angiogenesis, Meth-1 has been implicated in a variety of diseases. In cancer, Meth-1 is often downregulated, which allows for the uncontrolled growth of blood vessels that feed the tumor. Conversely, overexpression of Meth-1 has been associated with diseases characterized by insufficient blood vessel growth, such as coronary artery disease and peripheral artery disease.

Research

Research into Meth-1 has primarily focused on its potential as a therapeutic target in cancer. By inhibiting Meth-1, it may be possible to starve tumors of their blood supply, thereby inhibiting their growth. However, more research is needed to fully understand the role of Meth-1 in angiogenesis and its potential as a therapeutic target.

See also

• ADAMTS
• Angiogenesis
• Cancer